Conference Reports for NATAP

Back

14th CROI Conference on Retroviruses and Opportunistic Infections Los Angeles, California Feb 25-28, 2007     Tipranavir   Predictors of response to TPV/r in pediatric patients: results of BI1182.14/PACTG1051 (03/10/07)   Evaluation of Intracranial Hemorrhage in 49,610 HIV-Infected Veterans and California Medicaid Recipients (03/07/07)   Simpler genotype score to predict response to tipranavir (03/13/07)   New Details on Resistance to Darunavir and Tipranavir: TMC & Tipranavir not cross-resistant; new tipranavir genotypic resistance profile; TMC114 & amprenavir not cross-resistant; selection of mutations conferring resistance to TMC114 (03/13/07)   Tipranavir & TMC114 Not Cross-Resistant in Clinical Isolates Study: An Investigation into the influence of the Tipranavir-associated V82L/T mutations on the susceptibility to darunavir and brecanavir (03/13/07)   Predicted Risk of Coronary Heart Disease (CHD) with Tipranavir Exposure Compared to Conventional PI in the RESIST Trial (03/16/07)   Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions (03/19/07)   TMC-278 New NNRTI   48-week primary analysis of trial TMC278- C204: TMC278 demonstrates potent and sustained efficacy in ARV-naive patients (03/01/07)   TMC278 Matches Efavirenz in Treatment-Naive People - written by Mark Mascolini(03/01/07)   Two New HIV Drugs: NNRTI TMC278 and CCR5 Antagonist Maraviroc (03/07/07)   Hepatitis   In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07)   Entecavir HBV Therapy: does it have HIV activity? (03/05/07)   Hepatic Steatosis (30%) and Liver Function Abnormalities among HIV-Infected Persons (03/07/07)   Acute hepatitis C in men who have sex with men (MSM) is not only confined to those infected with HIV and they continue to increase (03/13/07)   CCR5 Anagonist - Maraviroc   CCR5 Blocker Looks Strong in Two International Salvage Trials - written by Mark Mascolini (02/28/07)   Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients - Press Release (03/02/07)   Maraviroc Combined Analysis & MOTIVATE 2 (Europe, Australia, USA): 24 week Results (03/01/07)   Pfizer CCR5 Maraviroc 24 Weeks In Treatment-Experienced (02/28/07)   Longitudinal Evaluation of Viral Co-receptor Tropism Switches among HIV-infected Patients with Drug-resistant Viremia (03/06/07)   Motivate 1 Study: Efficacy and Safety of Maraviroc plus Optimized Background Therapy In Viremic, ART-Experienced Patients Infected With CCR5-Tropic HIV-1: 24-Week Results of Phase 2b/3 Studies (03/05/07)   Assessing HIV-1 Tropism in ACTG A5211: A Comparison of Assays Using Replication-competent Virus from Peripheral Blood Mononuclear Cells (PBMC) Versus Plasma-derived Pseudotyped Virions (03/13/07)   Pfizer Tropism Assay: Evaluation of an Ultra-deep Sequencing Method to Identify Minority Sequence Variants in the HIV-1 env Gene from Clinical Samples (03/09/07)   TMC 114 - Darunavir   Darunavir-Amprenavir Cross-Resistance in Clinical Samples Submitted for Phenotype-Genotype Combination Resistance Testing (03/13/07)   TMC114 High Genetic Barrier To Resistance Due to Tight Binding to MDR HIV & Wild-Type (03/13/07)   Prior utilization/resistance to amprenavir at screening has minimal impact on the 48-week response to darunavir/r in the POWER 1, 2 and 3 studies (03/13/07)   Lipids, Metabolics, and Body Changes   ART Interruptions Increase Cardiovascular Disease Risk by 57% in SMART Study (03/27/07)   Interruption of ART & Risk of Cardiovascular Disease: findings from SMART (02/22/07)   Adverse Events/Complications of ART in Africa - written by Carl J. Fichtenbaum (03/01/07)   Lipodystrophy/Metabolic Complications of ART in South Africa - written by Carl J. Fichtenbaum (03/01/07)   Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163 (02/26/07)   Metabolic Outcomes of ACTG 5142: A Prospective, Randomized phase III trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial treatment of HIV-1 (02/26/07)   Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients (02/26/07)   Ezetimibe Reduces LDL-C for HIV+ on HAART (02/26/07)   How Antiretroviral Breaks May Raise Heart Disease Risk - written by Mark Mascolini (02/26/07)   Therapies for Improved Lipids, Belly Fat, and Limb Fat (02/26/07)   People With HIV Infection Eat Too Much Saturated Fat - written by Mark Mascolini (02/28/07)   Metabolic and Cardiovacular Complications in HIV - written by Carl J. Fichtenbaum, M.D. (03/01/07)   Osteopenia in HIV: risk factors for screening - written by Carl J. Fichtenbaum, M.D. (03/02/07)   Alendronate Modestly Improved BMD in 48 Week ACTG Study (03/07/07)   SUN Study: 10% Osteoporosis, 51% Osteopenia (03/07/07)   Metabolic Outcomes of ACTG 5142: A Prospective, randomized Phase III Trial of NRTI, PI, and NNRTI-sparing Regimens for Initial Treatment of HIV (03/05/07)   Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r (Kaletra) + AZT/3TC Induction Followed by LPV/r Monotherapy Compared with EFV +AZT/3TC (03/05/07)   Body Composition Changes in ARV-Naive Subjects Treated With Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 48-Week CT and DEXA Data (03/05/07)   Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study (03/07/07)   The Effects of Intermittent, CD4-Guided Antiretroviral Therapy on Peripheral Limb Fat and Metabolic Parameters: The SMART Body Composition Substudy (03/12/07)   Leptin Reduced VAT by 30%/Improved Metabolics in Pilot Study (03/12/07)   Factors Associated with the Incidence of Diabetes Mellitus Type 2 in HIV-Infected Participants of the Swiss HIV Cohort Study (03/12/07)   Improved Cardiac Disease Management, Risk for Myocardial Infarction Stabilizes (03/12/07)   Gut CD4s May Not Recover After HAART - Written By David Margolis, MD (03/12/07)   Higher ART TDF/FTC Potency Correlates with Increased Protection against Rectal SHIV Transmission (03/09/07)   Are HIV Docs Managing Lipids Correctly? (03/09/07)   Cardiovascular, Lipid, and Metabolic Complications of ART - written by Carl J. Fichtenbaum, M.D. - (05/29/07)   Lipoatrophy & Mitochondrial Toxicity - written by Carl J. Fichtenbaum, M.D. - (05/29/07)   Session 126 - Complications of ART in exposed and infected HIV children - written by Carl J. Fichtenbaum, M.D. - (05/29/07)   Integrase Inhibitors   Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of Raltegravir (MK-0518), a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus (03/05/07)   Opening last week in L.A.: the era of integrase inhibition? - Reported by David Margolis, MD (03/06/07)   Results from Two Phase III Studies on ISENTRESS (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) - Press Release (03/02/07)   In Vitro Resistance Profile of HIV-1 Mutants Selected by the HIV-1 Integrase Inhibitor, GS-9137 (JTK-303) (03/07/07)   A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy Subjects (GRZ105655) (03/07/07)   Gilead Integrase Inhibitor Outdoes New PIs in Salvage Therapy - written by Mark Mascolini (03/01/07)   The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients (03/01/07)   Integrase Inhibitor Adds More Punch to Salvage Regimens - written by Mark Mascolini (02/28/07)   AIDS & Non-AIDS Cancers   CD4 Count Predicts Fatal Non-AIDS Cancers: Traditional Malignancies May also be AIDS-Related - Reported by David Alain Wohl (03/05/07)   Lower CD4 Counts Boost Risk of "Non-AIDS" Cancers - written by Mark Mascolini (02/28/07)   CD4 Counts Predict Non-AIDS Disease Risk in FIRST Trial - written by Mark Mascolini (02/26/07)   Higher CD4 Count Prevents End-Organ Diseases (03/05/07)   Increased Prostate Cancer Incidence in Aging Population (03/07/07)   The Brain, Central Nervous System and Cognitive Impairment   This is your brain off drugs: the neurocognitive effects of treatment interruption - Written By David Margolis, MD (03/29/07)   Opening last week in L.A.: the era of integrase inhibition? - Written By David Margolis, MD (03/29/07)   HIV in CSF Associated with Neurological Impairment (03/06/07)   Important New Findings on HIV Control in the Brain, Neurocognitive Dysfunction, ART CNS-Penetration (03/07/07)   Starting Antiretrovirals Later May Hurt Cognitive Function - written by Mark Mascolini (02/26/07)   Reyataz   PK Atazanavir-based HAART in pregnancy (03/27/07)   Atazanavir Use in Pregnancy: a report of 33 cases (03/27/07)   PK of Reyataz & Reyataz/r: viral response, lipids, bilirubin, AEs (03/19/07)   Effect of Famotidine 20 and 40 mg Dosing Regimens on the Bioavailability of Atazanavir with Ritonavir in Combination with Tenofovir in Healthy Subjects (03/07/07)   Body Composition Changes in ARV-Naive Subjects Treated With Atazanavir or Atazanavir/Ritonavir-Based Once-Daily HAART: 48-Week CT and DEXA Data (03/05/07)   Effects of atazanavir or saquinavir QD with ritonavir 100 mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal; a randomised open-label study (03/07/07)   Kaletra   Predictors of Loss of Virologic Response in Subjects Who Deintensified to Lopinavir/ritonavir Monotherapy After Achieving Plasma HIV-1 RNA <50 copies/mL on Lopinavir/ritonavir Plus Zidovudine/lamivudine (03/07/07)   Single Agent Therapy with Lopinavir/ritonavir Controls HIV-1 Replication in the Central Nervous System (03/07/07)   Abbott Reports 4 Viral Decay Phases: Low-Level Viremia Decays Over 7+ Years to a Residual Level Correlated with Baseline HIV-1 RNA (Kaletra) (03/19/07)   CROI Other Topics   HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin (05/29/07)   Glucose Intolerance Associated with Advancing Liver Disease (Fibrosis) (05/29/07)   Non-Invasive Liver Tests Studies Disappoint at CROI in Coinfection Studies (05/29/07)   10% Resistance Rate in USA, Most Common Mutations in Naive Newly Diagnosed: CDC Report (04/02/07)   Bioequivalence of Pilot Tablet Formulations of Ritonavir (RTV) to the Marketed Soft gel Capsule (SGC) at a Dose of 100 mg (03/06/07)   Safety and Antiviral Activity of Fosamprenavir/Ritonavir (FPV/RTV) QD Regimens in HIV-Infected Pediatric Subjects Ages 2 to 18 Years (48 week Interim Data, Study APV20003) (03/19/07)   TMC125, Tenofovir, LPV/r Interactions (03/16/07)   Mortality & Causes of Death--and Chances of Avoiding It--With HIV Today (03/13/07)   CLINICAL PHARMACOLOGY AT THE 14TH CROI - Written by John G. Gerber, MD Jennifer J. Kiser, Pharm D (03/13/07)   Safety and Antiviral Activity of Fosamprenavir (FPV)-Containing Regimens in HIV-Infected 2 to 18 Year Old Pediatric Subjects (Interim Data, Study APV29005) (03/19/07)   HIV Pathogenesis in Humans & Monkeys - Written By David Margolis, MD (03/12/07)   Baseline Viral Load Predicts HIV Disease Progression & Baseline CD4 Count Predicts CD4 Decline in ART-Naives (03/12/07)   Viral Load is Best Predictor of AIDS & Death In Long Term (03/12/07)   Should We Start HAART Early Due to Gut Immune Depletion by HIV (03/12/07)   ART Drug Concentrations in the Genital Tract of HIV-Infected Women (03/12/07)   Hepatitis B Virus (HBV) Dynamics in HIV-HBV Co-infected Patients: Significant Difference in the Viral Activity of Adefovir (ADV) or Tenofovir (TDF) (03/09/07)   Substantial CD4+ T-cell Recovery and Reconstitution of Tissue Architecture in Gut-associated Lymphoid Tissue in Advanced HIV-1 Infection following Initiation of HAART with Nevirapine plus Trizivir (03/09/07)   Efficacy and Safety of Tenofovir DF (TDF)-containing versus non-TDF-containing Regimens in Black Antiretroviral-Naive Patients (03/09/07)   RNase H Inhibitors: Obstacles to Developments - Reported by David Margolis (03/09/07)   FTC/Tenefovir as a Rectal Gel Microbicide (03/09/07)   HIV Transmission Risk is Higher During ART Interruptions (03/07/07)   Insulin Resistance Predicts Rapid Response in People With HCV and HIV - written by Mark Mascolini (03/05/07)   HIV-Related Kidney Disease, ART Effects - Written by Christina Wyatt and Paul Klotman (03/05/07)   Acute HIV infection: Transmitted Resistance in Newly Infected Patients - written by Charles Hicks, M.D. (03/05/07)   Increase in AIDS Cases (03/02/07)   Disparities in Life Expectancy Due to Suboptimal HIV Care in the US: Impact of Gender, Ethnicity and Race: (03/02/07)   Preclinical Data From Two Novel NNRTI Idenix Compounds for the Treatment of HIV Presented at Conference on Retroviruses and Opportunistic Infections (CROI) (03/02/07)   Three new drugs promise options for HIV patients (03/01/07)   New HIV Drugs; Intl Drug Resistance (02/28/07)   Do Trace Levels of HIV Drug Resistance Transmitted During Infection Affect Virological Response? - written by Mark Mascolini (02/28/07)   Life Expectancy With HIV Still Low in High-Income Countries - written by Mark Mascolini (02/28/07)   HIV Drug Resistance Appears Low in Some Developing Countries (02/26/07)   Drug-resistant TB that kills HIV patients is spreading (02/26/07)